Figure 3.

Comparison of the distribution of prescriptions for the COPD patients who were reclassified from GOLD group D to B and the COPD patients remaining in group D. DB, patients switched from group D to B; DD, patients remaining in group D; THEO, theophylline; SABD, short-acting bronchodilator; SABA, short-acting beta-agonist; SAMA, short-acting muscarinic receptor agonist; LAMA, long-acting muscarinic receptor agonist; LABA, long-acting beta-agonist; ICS, inhaled corticosteroids; Triple, LAMA + LABA + ICS; COPD, chronic obstructive pulmonary disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease.